Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer

This publication has 51 references indexed in Scilit:

• Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers
  BMC Cancer, 2010
• Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer
  Journal of Translational Medicine, 2010
• Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy
  British Journal of Cancer, 2010
• In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy
  Journal of Proteomics, 2010
• DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response
  Molecular Cancer, 2010
• Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells
  Proceedings of the National Academy of Sciences, 2010
• Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation
  Clinical Cancer Research, 2010
• Identification of a Putative Protein Profile Associated with Tamoxifen Therapy Resistance in Breast Cancer
  Molecular & Cellular Proteomics, 2009
• A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines
  Molecular Cancer Therapeutics, 2009
• Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment
  Cancer Treatment Reviews, 2007